|Bid||0.0400 x 0|
|Ask||0.0450 x 0|
|Day's range||0.0450 - 0.0450|
|52-week range||0.0450 - 0.1200|
|Beta (5Y monthly)||1.30|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (VYYRF) (the “Company” or “Voyageur”) is pleased to announce it has signed an LOI with an established international mining company (the “Counterparty”) that has developed a low cost method to extract the natural occurring carbon molecule, C-60 to C-90, from large natural-occurring fullerene resources. “Voyageur will be the first company to be able to mass produce C-60 at a low cost, allowing for multiple drug products to be developed,” states Brent Willis, CEO of Voyageur Pharmaceuticals. “The barriers for C-60 based drugs has now been broken, which opens up the industry to develop new effective drugs and health care products on an economic scale,” continues Brent Willis.
Voyageur Pharmaceuticals Ltd. (VM.V) (the “Company” or “Voyageur”) is pleased to announce the dissolution of the current joint venture with Chief Medical Supplies (“Chief”). Voyageur and Chief have worked together to create a new working relationship that is more beneficial to both parties. Voyageur will move the projects forward using manufacturing agreements in place of the joint venture structure.
Voyageur Pharmaceuticals Ltd. (TSX.V:VM, USA:VYYRF) (the “Company” or “Voyageur”) is pleased to announce the fully-integrated iodine business strategy which complements its ongoing barium contrast marketing strategy. Iodine contrast is one of highest volume consumables in healthcare. Water soluble, iodinated contrast media contains iodine atoms used for x-ray-based imaging such as computed tomography (CT), fluoroscopy, angiography and venography.